This week's View focuses on heart disease in women, addressing the long-term risk of developing heart failure (HF) after trastuzumab therapy, how sex differences contribute to exercise intolerance in patients with HF with preserved ejection fraction, and gender differences in adverse drug reactions to HF medication.

Subscribe on iTunes | Subscribe on Google Play

Clinical Topics: Arrhythmias and Clinical EP, Cardio-Oncology, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Noninvasive Imaging, Prevention, Atherosclerotic Disease (CAD/PAD), Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Echocardiography/Ultrasound, Hypertension

Keywords: EaglesEyeView, Anthracyclines, Atrial Fibrillation, Adrenergic beta-Antagonists, Adverse Drug Reaction Reporting Systems, Angiotensin II Type 2 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Breast Neoplasms, Cardiac Catheterization, Cardiotoxicity, Cardiovascular Agents, Chemotherapy, Adjuvant, Coronary Artery Disease, Diabetes Mellitus, Type 2, Diastole, Diagnostic Imaging, Drug-Related Side Effects and Adverse Reactions, Echocardiography, Exercise Tolerance, Heart Failure, Ergometry, Hypertension, Lactic Acid, Hemodynamics, Lung Diseases, Mineralocorticoid Receptor Antagonists, Myocardial Infarction, Pulmonary Disease, Chronic Obstructive, Risk, Pulmonary Wedge Pressure, Secondary Prevention, Sex Characteristics, Vascular Diseases, Stroke Volume, Women, Workload

< Back to Listings